Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer
10.3760/cma.j.issn.0253-3766.2017.06.001
- VernacularTitle: 第三代表皮生长因子受体酪氨酸激酶抑制剂对非小细胞肺癌的作用机制和临床疗效
- Author:
Xiaoxia CHEN
1
;
Caicun ZHOU
1
Author Information
1. Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China
- Publication Type:Review
- Keywords:
Carcinoma, non-small cell lung;
Epidermal growth factor receptor-tyrosine kinase inhibitors;
Drug resistance;
T790M mutation;
Drug therapy
- From:
Chinese Journal of Oncology
2017;39(6):401-404
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. However, most of patients will develop resistance to TKIs treatment due to the emergence of the T790M mutation. The third-generation EGFR-TKI is highly selective and efficient for activating mutants (EGFR sensitive mutations) and resistance mutant (T790M+ ). This review summarizes the mechanism and clinical efficacy of the third-generation EGFR-TKI in NSCLC patients.
